This study is designed to evaluate the efficacy and safety of the combination treatment of Huaier granule and biliary drainage for malignant obstructive jaundice.
After sign the informed consent, the, eligible patients are those who have completed the examinations within 2 weeks after the biliary drainage will enter the study and visit the study sites at Weeks 12, 24, 36, and 48. The follow-up duration is up to 48 weeks or until the death of patient during the study. The patients will be allocated to two groups based on whether being exposed to Huaier granule or not. Study data will be collected prospectively, including the patients' baseline characteristics, chemo-/radio-therapy history, previous Huaier granule treatment, laboratory tests, imaging examinations, and various clinical endpoints including liver function, quality of life, status of survival, and safety. This is a non-interventional study in patient population in real world. Therefore, the patients' treatment regimen will not be interfered, i.e., the patients will independently decide whether to take Huaier granule or not based on the recommendation from the clinician after the drainage. The patients will be allocated into different groups completely according to their treatment at clinic in real world. During the study, only the study required data and endpoints will be collected.
Study Type
OBSERVATIONAL
Enrollment
852
Overall survival
the time interval between baseline and the time of death due to any cause
Time frame: every 12 weeks until death, up to 48 weeks
overall survival rate
Overall survival rate at 48 weeks was defined as the proportion of patients who were alive at 48 weeks
Time frame: 48 weeks
Median survival time (MST)
indicate the survival time when only 50% of patients are still alive.
Time frame: 48 weeks
Karnofsky (KPS) score
improved is defined as KPS increases \>10 after treatment; worsen is defined as KPS decreases \>10; stable is defined as KPS changes ≤10.
Time frame: 48 weeks
Liver function 1
Measurement of direct bilirubin
Time frame: 12、24、36、48 weeks
Liver function 2
Measurement of total bilirubin
Time frame: 12、24、36、48 weeks
Liver function 3
the time of reoccurrence of jaundice.
Time frame: 12、24、36、48 weeks
Quality of Life (QoL) score
Quality of Life (QOL) were measured using supplemental quality of life questions. Item score range(12 items): 1(worst symptom) to 5 (no symptom). Change: score at 48 weeks minus score at baseline.
Time frame: 48 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Adverse Events
Incidence rate of Adverse events
Time frame: 12、24、36、48 weeks